Affinity Asset Advisors LLC Sells 100,000 Shares of Abivax SA Sponsored ADR $ABVX

Affinity Asset Advisors LLC trimmed its position in Abivax SA Sponsored ADR (NASDAQ:ABVX) by 19.8% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 405,000 shares of the company’s stock after selling 100,000 shares during the quarter. Abivax accounts for approximately 2.3% of Affinity Asset Advisors LLC’s holdings, making the stock its 12th biggest holding. Affinity Asset Advisors LLC’s holdings in Abivax were worth $45,097,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in ABVX. GHP Investment Advisors Inc. boosted its holdings in shares of Abivax by 155.6% during the first quarter. GHP Investment Advisors Inc. now owns 230 shares of the company’s stock worth $26,000 after purchasing an additional 140 shares during the period. Bank of America Corp DE raised its holdings in shares of Abivax by 56.1% during the fourth quarter. Bank of America Corp DE now owns 5,536 shares of the company’s stock valued at $41,000 after acquiring an additional 1,990 shares in the last quarter. Caitong International Asset Management Co. Ltd raised its holdings in shares of Abivax by 661.5% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 396 shares of the company’s stock valued at $53,000 after acquiring an additional 344 shares in the last quarter. WPG Advisers LLC lifted its stake in Abivax by 125.9% in the fourth quarter. WPG Advisers LLC now owns 454 shares of the company’s stock worth $61,000 after acquiring an additional 253 shares during the period. Finally, T. Rowe Price Investment Management Inc. bought a new stake in Abivax in the fourth quarter valued at $61,000. 47.91% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several research firms have recently commented on ABVX. HC Wainwright reaffirmed a “buy” rating on shares of Abivax in a research report on Tuesday, June 30th. Weiss Ratings reissued a “sell (d-)” rating on shares of Abivax in a research note on Friday, July 17th. Jefferies Financial Group upgraded shares of Abivax from a “hold” rating to a “buy” rating and raised their price objective for the stock from $108.00 to $158.00 in a report on Tuesday, June 30th. Piper Sandler upped their target price on Abivax from $165.00 to $175.00 and gave the stock an “overweight” rating in a report on Thursday, July 9th. Finally, Morgan Stanley reissued an “overweight” rating and issued a $180.00 target price on shares of Abivax in a research report on Friday. Thirteen analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Abivax presently has an average rating of “Moderate Buy” and a consensus target price of $156.50.

Abivax Stock Down 4.2%

Shares of ABVX opened at $125.70 on Friday. Abivax SA Sponsored ADR has a twelve month low of $65.67 and a twelve month high of $148.83. The company has a market capitalization of $10.96 billion, a P/E ratio of -24.13 and a beta of 0.87. The firm has a 50 day moving average of $117.99 and a 200 day moving average of $118.26.

Abivax (NASDAQ:ABVX) last issued its earnings results on Friday, May 22nd. The company reported ($0.71) EPS for the quarter, beating the consensus estimate of ($0.94) by $0.23. The business had revenue of $1.56 million for the quarter, compared to analysts’ expectations of $0.40 million. On average, sell-side analysts expect that Abivax SA Sponsored ADR will post -3.4 EPS for the current year.

About Abivax

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.